8-K: Tivic Health Pivots to Biopharma, Exits ClearUP Business

Tivic Health Systems, Inc. announced its third quarter 2025 financial results and a strategic pivot to focus solely on its biopharma pipeline, winding down its ClearUP consumer health business.

Summary

• Tivic Health Systems, Inc. is winding down its ClearUP consumer health business, with substantial completion expected by year-end 2025.
• The company will now primarily focus on its biopharma program and the development of biopharmaceutical product candidates, including Entolimod for acute radiation syndrome (ARS), neutropenia, and cancer-related conditions, and its vagus nerve stimulation (VNS) device.
• In Q3 2025, Tivic incurred approximately $347,000 in charges related to the ClearUP wind-down, comprising a $230,000 inventory reserve and $117,000 in other expenses, with an additional $20,000 to $50,000 expected by year-end.
• The company expects minimal to no revenue until its biopharma product candidates receive regulatory approval and are commercialized.
• Net loss for Q3 2025 was $2.6 million, compared to $1.4 million in Q3 2024.
• Cash and cash equivalents stood at $3.5 million as of September 30, 2025, up from $2.0 million at December 31, 2024.
• Tivic closed $3.8 million in net proceeds from its $8.4 million financing during Q3 2025.
• The company has no debt on its balance sheet and believes current and committed funding ($3.5 million available) is sufficient for Entolimod manufacturing validation.

Sentiment

Score: 4

Explanation: The strategic pivot to biopharma is a long-term positive, but the immediate financial results are poor, with increased losses and a significant revenue gap expected from the ClearUP exit. The company is in a high-risk, early-stage development phase for its new focus, despite some progress in IND transfers and manufacturing steps.

Positives

• Successfully completed the transfer of two Investigational New Drug (IND) applications from Statera Biopharma, enabling clinical trials for Entolimod in neutropenia and cancer-related conditions.
• Completed cell line verification, a critical first step for Current Good Manufacturing Practices (cGMP) required prior to filing a Biologics License Application (BLA) with the U.S. Food & Drug Administration (FDA).
• Advanced discussions with key government agencies regarding potential pathways to deploying Entolimod as a military medical countermeasure and stockpile drug for acute radiation syndrome (ARS).
• Closed $3.8 million in net proceeds from the second, third, and fourth tranches of an $8.4 million financing during Q3 2025, contributing to a cash balance of $3.5 million with no debt.
• Compelling findings from the VNS Optimization Trial uncovered new insights into vagus nerve stimulation, leading to additional patent filings for prescription device development.
• Gross margin, excluding the $230,000 inventory reserve, improved to 42% in Q3 2025 from 35% in Q3 2024.

Negatives

• The company incurred a gross loss of $145,000 in Q3 2025, compared to a gross profit of $44,000 in Q3 2024, primarily due to a $230,000 inventory reserve recorded in connection with the ClearUP wind-down.
• Operating expenses increased significantly to $2.3 million in Q3 2025 from $1.5 million in Q3 2024, driven by the addition of the biopharma business and increased corporate and advertising costs related to the ClearUP exit.
• Net loss widened to $2.6 million in Q3 2025 from $1.4 million in Q3 2024.
• The wind-down of the ClearUP business is expected to result in minimal to no revenue until biopharma product candidates achieve regulatory approval and commercialization.
• The company incurred approximately $347,000 in charges in Q3 2025 and expects an additional $20,000 to $50,000 in expenditures through year-end related to the ClearUP exit.

Risks

• Actual results may differ materially from estimates of charges, costs, and revenue expectations related to the ClearUP wind-down due to a number of assumptions.
• The company may incur other charges or cash expenditures not currently contemplated due to unanticipated events that may occur as a result of or in connection with the wind-down of the ClearUP business.
• Risks associated with interactions and guidance from the FDA and other regulatory authorities.
• Uncertainty regarding the timing and success of clinical trials and study results for its product candidates.
• Potential failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations.
• Challenges in securing orders for product candidates if regulatory approvals are obtained.
• Risks related to the future development of the ncVNS treatment, Entolimod, and Entolasta.
• Changes to the company's business strategy, regulatory requirements, and pathways for approval.
• Changes to the company's relationship with its partners, including its manufacturing partners and other third-party providers.
• Uncertainty regarding the consummation of any strategic transactions.
• The company's need for, and ability to secure when needed, additional working capital.
• Unexpected costs or expenses, or other issues, that may arise in connection with the wind-down of its consumer health business.
• The company's ability to maintain its Nasdaq listing.
• Changes in tariffs, inflation, legal, regulatory, political, and economic risks.

Future Outlook

Tivic Health Systems, Inc. expects minimal to no revenue until its biopharma product candidates achieve regulatory approval and commercialization. The company believes its current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Management is encouraged by interest in Entolimod as a military medical countermeasure and stockpile drug and continues to advance towards commercial readiness, including cGMP manufacturing. The company also plans to initiate clinical trials for Entolimod in neutropenia and cancer-related conditions and is pursuing patent filings for its prescription vagus nerve stimulation device development.

Management Comments

• "Following our discussions at the Military Health System Research Symposium and continued engagement with key government agencies, we are encouraged by the interest in our lead product candidate, Entolimod for acute radiation syndrome (ARS), as a military medical countermeasure and stockpile drug."
• "This quarter, we continued the advancement towards commercial readiness. Starting the cGMP manufacturing process with successful cell line verification was a critical first step to establishing reproducibility and scalability in our drug manufacturing."
• "Subsequent to the quarters end, we also reported the compelling findings from Tivics VNS Optimization Trial. These findings uncovered new insights into vagus nerve stimulation and have led to additional patent filings intended to protect Tivics prescription device development for commercialization and licensing."

Industry Context

Tivic Health's strategic pivot from consumer health tech to a pure-play immunotherapeutics company aligns with a broader industry trend of specialization and focus on high-value, often government-backed, biopharmaceutical development, particularly in areas like medical countermeasures. The focus on TLR5 agonists and vagus nerve stimulation places Tivic in competitive and innovative segments of immunology and bioelectronics, respectively. The pursuit of Entolimod as a military medical countermeasure taps into a niche but significant market driven by national security and public health preparedness, potentially offering a more stable revenue stream compared to consumer electronics.

Comparison to Industry Standards

• The shift to a biopharma-focused model, particularly for medical countermeasures like Entolimod for ARS, is comparable to companies developing specialized drugs for government stockpiles, such as Emergent BioSolutions (anthrax vaccines, smallpox vaccines) or Bavarian Nordic (smallpox vaccine). These companies often rely on government contracts and regulatory pathways like the FDA's Animal Rule.
• The development of Entolimod as a TLR5 agonist for ARS, neutropenia, and cancer-related conditions positions Tivic in a competitive landscape with other immunomodulatory drug developers. For example, companies like Dynavax Technologies (TLR9 agonist) or Idera Pharmaceuticals (TLR9 agonist) have explored similar pathways for oncology and infectious diseases, though specific ARS countermeasures are less common.
• The bioelectronic program, focusing on vagus nerve stimulation (VNS) devices, places Tivic alongside companies like LivaNova (implantable VNS for epilepsy/depression) and electroCore (non-invasive VNS for headache disorders). Tivic's aim for non-invasive devices with comparable or better outcomes than implanted ones suggests a competitive strategy in the growing neuromodulation market.

Stakeholder Impact

• Shareholders: Significant strategic shift introduces high risk and long-term potential. Immediate financial performance is negative, with a period of minimal revenue expected. Dilution from recent financing.
• Customers (ClearUP): Direct sales and advertising discontinued, with only reseller orders fulfilled through Q4 2025, indicating an end to product availability.
• Employees: Implied workforce reduction or reallocation associated with the ClearUP business wind-down.
• Creditors: No debt on the balance sheet, which is positive.
• Suppliers (ClearUP): Discontinuation of ClearUP production will impact suppliers.

Next Steps

• Substantially complete the wind-down of the ClearUP business prior to the end of 2025.
• Continue to advance the development of biopharmaceutical product candidates.
• Initiate clinical trials for Entolimod in neutropenia and cancer-related conditions.
• Continue progress toward manufacturing validation for Entolimod.
• Pursue additional patent filings for prescription vagus nerve stimulation device development.
• Fulfill orders from ClearUP resellers through the fourth quarter of 2025.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation, exiting a revenue-generating but unprofitable consumer business to focus on a high-potential, but high-risk, biopharma pipeline. While the long-term potential of Entolimod as a military countermeasure and the VNS device is intriguing, the immediate financial outlook is challenging, with widening losses and an expected period of minimal revenue. The recent capital raise provides some runway, but future funding needs are likely. Given the early stage of the biopharma programs and the inherent risks of drug development, a 'hold' recommendation is appropriate for investors who can tolerate high risk and are willing to wait for clinical milestones and regulatory progress. New investors should exercise caution due to the speculative nature of the new business model.

Keywords

Tivic Health Systems, TIVC, Biopharma, ClearUP, Acute Radiation Syndrome, ARS, Entolimod, TLR5 agonist, Neutropenia, Lymphocyte Exhaustion, Cancer-related conditions, Vagus Nerve Stimulation, VNS, Medical Countermeasure, FDA, IND, cGMP, Biologics License Application, BLA, Strategic Transformation, Immunotherapeutics, Financial Results, Q3 2025, Nasdaq